Posted in | News | Materials Analysis

Rigaku Announces Grant Assistance Program to Help Support Illicit Narcotics Interdiction

Rigaku Analytical Devices today announced the launch of its new narcotics identification grant assistance program in partnership with Lexipol’s PoliceGrantsHelp.com. Rigaku’s new service is designed to provide law enforcement departments and agencies that qualify for Rigaku devices, but may not have the funding, with the resources required to successfully identify and apply for federal, state, corporate, and private grants to purchase these critical tools.

Image Credit: Rigaku Analytical Devices

Rigaku’s handheld 1064 nm Raman CQL Series analyzers are now part of PoliceGrantsHelp.com. The Rigaku portfolio of handheld 1064 nm Raman analyzers are designed to deliver comprehensive analysis of unknown substances in the field. The CQL series is comprised of three variants to best fit the budget and performance needs of every department at a federal, state, county, and local level.

With a focus on illicit narcotics analysis, the CQL Narc-ID handheld Raman analyzer offers presumptive identification of narcotics, precursor chemicals, and cutting agents. The Rigaku CQL Gen-ID handheld Raman analyzer expands chemical threat analysis with a library that also includes more general threats, including explosives and general chemicals. To maximize chemical threat analysis response capability, including chemical warfare agents, Rigaku’s CQL Max-ID handheld Raman analyzer features the largest on-board library, that can identify of over 13,000 items including narcotics, explosives, toxic chemical industrial chemicals, chemical warfare agents (CWAs), and more.

The utilization of 1064 nm Raman technology means users can safely scan through translucent materials, minimizing the need to open any packaging or containers. The 1064 nm wavelength also better handles fluorescence and allows a greater ability to identify dirty or mixed substances at the point of need, a common issue for older Raman technology. In addition, all Rigaku CQL Series Raman analyzers have the ability to detect non-visible substances with the optional QuickDetect feature.

“We’re very pleased to offer this grant assistance program to those departments who are in need of securing funding to procure equipment that will make our communities safer,” said Michael Brown, Global Director for Counter-Narcotics Technology. “The illicit street drug market has never been more dangerous, and it’s more critical than ever that our first responders and law enforcement personnel are equipped with technology that is going to provide real-time analysis of current and emerging chemical threats – with fast results at their fingertips.”

The Rigaku CQL Series is supported by Rigaku’s global sales and distribution channels.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Rigaku Corporation. (2024, February 02). Rigaku Announces Grant Assistance Program to Help Support Illicit Narcotics Interdiction. AZoM. Retrieved on December 03, 2024 from https://www.azom.com/news.aspx?newsID=62494.

  • MLA

    Rigaku Corporation. "Rigaku Announces Grant Assistance Program to Help Support Illicit Narcotics Interdiction". AZoM. 03 December 2024. <https://www.azom.com/news.aspx?newsID=62494>.

  • Chicago

    Rigaku Corporation. "Rigaku Announces Grant Assistance Program to Help Support Illicit Narcotics Interdiction". AZoM. https://www.azom.com/news.aspx?newsID=62494. (accessed December 03, 2024).

  • Harvard

    Rigaku Corporation. 2024. Rigaku Announces Grant Assistance Program to Help Support Illicit Narcotics Interdiction. AZoM, viewed 03 December 2024, https://www.azom.com/news.aspx?newsID=62494.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.